NCT06230445 Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
| NCT ID | NCT06230445 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sun Yat-sen University |
| Condition | Application of Digital Therapeutic in Lung Cancer Whole Process Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 900 participants in total. It began in 2023-06-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial will randomize patients into two groups, the treatment group will use the digital therapeutic application named 'UHealth' for the whole process management and the control group will use regular follow-up. The trial aims to look into the difference between quality of life, anxiety/depression index, emergency treatment times, hospital admission rate, treatment compliance, OS, DFS and follow-up cost.
Eligibility Criteria
Inclusion Criteria: * Patients with histologically or cytologically confirmed lung cancer; * Patients have received surgery, neoadjuvant therapy, adjuvant therapy, radiotherapy or other chemotherapy, such as cytotoxic chemotherapy, targeted therapy and immunotherapy; * ECOG (Performance status) 0-1; * Patients aged \> 18 years and \< 70 years; * The patients themselves or their family members are familiar with mobile and internet; Exclusion Criteria: * Patients have disease progression in the screening period; * Patients with symptomatic brain metastasis; * Patients with dementia, schizophrenia or other psychological diseases that may affect the cognitive behavior; * Other medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information; * Women who are pregnant or in the period of breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06230445 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Application of Digital Therapeutic in Lung Cancer Whole Process Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06230445 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 900 participants.
Is NCT06230445 currently recruiting?
Yes, NCT06230445 is actively recruiting participants. Contact the research team at longhao@sysucc.org.cn for enrollment information.
Where is the NCT06230445 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06230445 clinical trial?
NCT06230445 is sponsored by Sun Yat-sen University. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.